Chief Medical Officer
Noah Berkowitz, M.D., Ph.D., is the Chief Medical Officer at Arvinas, Inc. (ARVN), a clinical-stage biopharmaceutical company, a position he has held since March 18, 2024.[[1]](https://fintool.com/app/research/companies/ARVN/people/noah-berkowitz)[[4]](https://www.arvinas.com/about-us/leadership/) At 61 years old, he brings over 20 years of drug development leadership in hematology, oncology, and rare diseases, including global regulatory approvals at Bristol-Myers Squibb and senior clinical roles at Novartis.[[1]](https://fintool.com/app/research/companies/ARVN/people/noah-berkowitz)
Berkowitz previously served as Senior Vice President, Hematology Development at Bristol-Myers Squibb (2020–2023), where his teams secured approvals for small molecules, biologics, and cell therapies, and as VP Clinical Development Head, Hematology at Novartis (2012–2020), leading development in rare diseases, oncology, and hematology.[[1]](https://fintool.com/app/research/companies/ARVN/people/noah-berkowitz) Earlier, he was founder and CEO of Synvista, executive at Impath (acquired by Genzyme), trained in Medical Oncology at the National Cancer Institute, and earned his M.D., Ph.D. from Columbia University.[[1]](https://fintool.com/app/research/companies/ARVN/people/noah-berkowitz) On February 13, 2026, shares were sold automatically on his behalf to cover tax withholding on vesting RSUs, with him retaining 163,938 shares post-transaction.[[3]](https://www.investing.com/news/insider-trading-news/arvinas-arvn-chief-medical-officer-berkowitz-sells-67594-in-stock-93CH-4512384)
View full insider profile →
